PCa progression outcomes vary by surgeon experience

San Francisco--Surgeon experience is an independent predictor of PSA progression in men undergoing radical prostatectomy, but among high-volume surgeons (those who performed more than 100 procedures) operating in a single institution, the individual surgeon alone is also a significant prognostic factor, according to a study by researchers at Memorial Sloan-Kettering Cancer Center, New York.

Related Videos

Sarah Razavi, MD, outlines strategies for mitigate surgeon discomfort during URS

Can ctDNA detect molecular residual disease in NMIBC?

Expert discusses setting realistic expectations for Rezum for BPH

Considering Therapy De-Intensification: Balancing Adverse Effects and PSA Response

Nicolette G. Payne, MD, discusses risk factors for burnout among pediatric urologists

Sacral neuromodulation device empowers patients with greater UUI control

Howard Goldman, MD, on his experience with the Glean Urodynamics System

Remaining Unmet Needs in NMIBC: Closing Thoughts From Expert Panel

Urology Crossroads: Looking Ahead in the Era of Immunotherapy for NMIBC

Study: Women with SCI are more likely to use indwelling catheters

Related Content

Advertisement

July 22nd 2025

Irreversible electroporation with NanoKnife found safe, effective for prostate tissue ablation

Hannah Clarke

The PRESERVE trial met its primary end point by demonstrating a negative in-field biopsy rate of 71% at 12 months.

July 15th 2025

Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD

Amy M. Pearlman, MD

Mulhall offers an unfiltered, evidence-based deep dive into testosterone evaluation and treatment nuances.

July 21st 2025

Darolutamide plus ADT approved in EU for mHSPC

Hannah Clarke

This approval enables the use of darolutamide plus ADT with or without chemotherapy.

June 30th 2025

Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD

Amy M. Pearlman, MD

Pearlman and Parekattil dig deep into novel surgical and non-surgical approaches to chronic orchialgia and pelvic pain.

July 18th 2025

Experts urge FDA to remove black box warning on low-dose vaginal estrogen

Hannah Clarke

In a panel meeting convened by the FDA, experts urged the agency to revise or remove the outdated boxed warning on hormone therapies for menopause.

July 18th 2025

Phase 3 TALAPRO-2 data of talazoparib plus enzalutamide published in The Lancet

Hannah Clarke

In both cohorts, the combination of talazoparib plus enzalutamide led to a significant improvement in overall survival vs enzalutamide alone.

Related Content

Advertisement

July 22nd 2025

Irreversible electroporation with NanoKnife found safe, effective for prostate tissue ablation

Hannah Clarke

The PRESERVE trial met its primary end point by demonstrating a negative in-field biopsy rate of 71% at 12 months.

July 15th 2025

Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD

Amy M. Pearlman, MD

Mulhall offers an unfiltered, evidence-based deep dive into testosterone evaluation and treatment nuances.

July 21st 2025

Darolutamide plus ADT approved in EU for mHSPC

Hannah Clarke

This approval enables the use of darolutamide plus ADT with or without chemotherapy.

June 30th 2025

Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD

Amy M. Pearlman, MD

Pearlman and Parekattil dig deep into novel surgical and non-surgical approaches to chronic orchialgia and pelvic pain.

July 18th 2025

Experts urge FDA to remove black box warning on low-dose vaginal estrogen

Hannah Clarke

In a panel meeting convened by the FDA, experts urged the agency to revise or remove the outdated boxed warning on hormone therapies for menopause.

July 18th 2025

Phase 3 TALAPRO-2 data of talazoparib plus enzalutamide published in The Lancet

Hannah Clarke

In both cohorts, the combination of talazoparib plus enzalutamide led to a significant improvement in overall survival vs enzalutamide alone.